Drugs that contain Dasatinib

1. List of Sprycel drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7491725 BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Mar, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8680103 BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Feb, 2025

(1 year, 11 months from now)

US8680103

(Pediatric)

BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Aug, 2025

(2 years from now)

US7491725

(Pediatric)

BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Sep, 2026

(3 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 21, 2025
Pediatric Exclusivity (PED) May 9, 2025

Market Authorisation Date: 28 June, 2006

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of SPRYCEL before it's patent expiration?
More Information on Dosage

SPRYCEL family patents

14

United States

3

Korea, Republic of

3

Japan

2

Brazil

2

Australia

2

Argentina

2

Russia

2

Norway

2

Canada

2

Taiwan, Province of China

2

European Union

1

Austria

1

Hong Kong

1

Poland

1

Spain

1

Germany

1

Israel

1

Cyprus

1

Mexico

1

Slovenia

1

South Africa

1

Portugal

1

Georgia

1

Peru

1

Croatia

1

China

1

New Zealand

1

India

1

Denmark

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic